A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope

Area of Science:

• Virology
• Immunology
• Cell Biology

Background:

• Understanding the human immunodeficiency virus (HIV) envelope is crucial for developing effective interventions.
• Existing methods for studying HIV envelope proteins often involve complex viral systems.
• A simplified, virus-free system is needed to investigate HIV envelope functions and immune responses.

Purpose of the Study:

• To develop a safe and effective cell-based system for exploring human immunodeficiency virus (HIV) envelope functions.
• To create a model that mimics viral envelopes and infected cells for research.
• To evaluate the potential of this system as a vaccine candidate.

Main Methods:

• Generation of a human lymphoid cell line (TF228.1.16) stably expressing functional HIV envelope proteins.
• Utilizing the TF228.1.16 cell line to study syncytia formation with CD4+ cells.
• In vitro and in vivo immunization experiments using the TF228.1.16 cell line with human peripheral blood mononuclear cells (PBMC) and rhesus monkeys.

Main Results:

• The TF228.1.16 cell line effectively mimics viral envelopes and infected cells, forming syncytia with CD4+ cells.
• This virus-free system facilitates the study of syncytia formation mechanisms and the evaluation of agents disrupting this process.
• Immunization with TF228.1.16 cells induced antibodies with neutralizing (anti-syncytia) activities in both in vitro and in vivo models.

Conclusions:

• The TF228.1.16 cell line provides a valuable virus-free platform for studying HIV envelope biology and function.
• This system offers a unique approach to presenting HIV envelope proteins to the immune system, potentially leading to novel immune protection strategies.
• The TF228.1.16 cell line demonstrates promise as a vaccine candidate for eliciting neutralizing antibodies against HIV.